1. Home
  2. SSM vs CALC Comparison

SSM vs CALC Comparison

Compare SSM & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSM

Sono Group N.V. Ordinary Shares

N/A

Current Price

$5.23

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.60

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSM
CALC
Founded
2016
2011
Country
Germany
United States
Employees
43
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
9.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SSM
CALC
Price
$5.23
$0.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
64.2K
179.0K
Earning Date
05-20-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1,462,987.20
N/A
Revenue Next Year
$48.49
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.34
$0.46
52 Week High
$10.54
$7.20

Technical Indicators

Market Signals
Indicator
SSM
CALC
Relative Strength Index (RSI) 33.00 44.11
Support Level N/A $0.50
Resistance Level $7.43 $0.78
Average True Range (ATR) 0.76 0.04
MACD -0.08 0.01
Stochastic Oscillator 12.22 50.69

Price Performance

Historical Comparison
SSM
CALC

About SSM Sono Group N.V. Ordinary Shares

Sono Group NV is engaged in the field of solar-powered electric mobility. With its proprietary solar technology, the company is able to integrate solar panels into a vehicle's bodywork, using energy captured from the sun to charge the vehicle's battery. The group is engaged in the design and development of its own first solar electric vehicle, the Sion. Its Products and Services includes Complete Solar Solutions, Solar Charge Controllers, Solar Modules, and Data Services and Engineering Services.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.

Share on Social Networks: